上海医药
(601607)
| 流通市值：458.27亿 | | | 总市值：609.28亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 31,212,245,657.38 | 32,721,763,351.58 | 36,731,758,748.4 | 39,094,785,250.94 |
| 交易性金融资产 | 9,904,370,812.87 | 10,360,938,931.51 | 7,816,270,273.97 | 8,404,903,589.04 |
| 衍生金融资产 | 80,274.74 | 721,010.06 | 994,853.52 | 4,918,514.43 |
| 应收票据及应收账款 | 91,981,694,328.42 | 83,336,971,509.14 | 89,848,665,692.43 | 87,219,561,553.39 |
| 其中：应收票据 | 831,905,512.76 | 1,030,570,879.31 | 1,065,609,050.48 | 841,716,223.13 |
| 应收账款 | 91,149,788,815.66 | 82,306,400,629.83 | 88,783,056,641.95 | 86,377,845,330.26 |
| 应收款项融资 | 1,874,956,792.4 | 2,528,730,548.02 | 1,668,551,993.81 | 1,911,121,780.41 |
| 预付款项 | 2,060,988,961.4 | 1,621,546,115.42 | 2,099,544,705.72 | 2,652,933,938.8 |
| 其他应收款合计 | 2,921,383,716.98 | 3,113,104,316.93 | 2,892,025,630.93 | 3,076,379,090.27 |
| 应收股利 | 18,742,898.66 | 18,742,898.66 | 24,812,649.82 | 8,012,649.82 |
| 存货 | 41,681,805,607.04 | 45,358,947,550.04 | 41,783,787,540.93 | 40,899,076,963.47 |
| 一年内到期的非流动资产 | 51,052,945.98 | 87,403,889.78 | 53,100,734.44 | 59,048,697.08 |
| 其他流动资产 | 1,152,864,021.04 | 1,333,568,015.3 | 1,033,573,215.36 | 1,134,024,657.5 |
| 流动资产合计 | 182,841,443,118.25 | 180,463,695,237.78 | 183,928,273,389.51 | 184,456,754,035.33 |
| 非流动资产: | | | | |
| 长期应收款 | 342,693,723.21 | 307,934,020.34 | 332,460,022.77 | 342,376,568.05 |
| 长期股权投资 | 7,037,227,345.15 | 7,010,202,458.66 | 7,024,473,181.92 | 6,895,330,823.14 |
| 其他权益工具投资 | 24,026,623.59 | 32,683,905.48 | 37,904,676.94 | 34,537,342.18 |
| 其他非流动金融资产 | 1,549,962,438.2 | 1,545,310,713.45 | 1,500,578,595.7 | 1,717,717,621.06 |
| 投资性房地产 | 361,866,216.01 | 411,930,954.28 | 378,436,621.72 | 422,069,186.59 |
| 固定资产 | 15,223,546,056.78 | 15,493,395,192.45 | 14,691,331,801.29 | 14,951,135,063.63 |
| 在建工程 | 2,081,774,632.17 | 1,994,094,180.71 | 2,475,535,410.2 | 2,382,163,131.76 |
| 生产性生物资产 | 5,751,402.87 | 4,774,514.95 | 4,615,299.69 | 8,461,853.96 |
| 使用权资产 | 1,932,708,925.01 | 1,793,806,208.1 | 1,823,101,868.08 | 1,895,536,449.93 |
| 无形资产 | 8,632,619,257.63 | 8,743,750,239.23 | 8,938,603,644.35 | 9,164,485,474.51 |
| 开发支出 | 102,871,193.91 | 103,244,846.29 | 220,546,205.27 | 222,370,286.93 |
| 商誉 | 12,666,528,950.87 | 12,665,615,569.87 | 12,735,504,562.05 | 12,836,417,573.07 |
| 长期待摊费用 | 527,728,780.55 | 546,294,913.19 | 540,670,515.05 | 556,439,540.26 |
| 递延所得税资产 | 1,692,445,192.66 | 1,640,049,019.47 | 1,733,733,678.37 | 1,718,921,891.13 |
| 其他非流动资产 | 346,289,831.38 | 391,984,792.96 | 380,475,763.31 | 462,339,229.84 |
| 非流动资产合计 | 52,528,040,569.99 | 52,685,071,529.43 | 52,817,971,846.71 | 53,610,302,036.04 |
| 资产总计 | 235,369,483,688.24 | 233,148,766,767.21 | 236,746,245,236.22 | 238,067,056,071.37 |
| 流动负债: | | | | |
| 短期借款 | 46,702,003,108.98 | 44,091,821,016.96 | 44,490,364,239.86 | 45,621,718,368.07 |
| 衍生金融负债 | 18,878,426.51 | 13,294,428.53 | 10,957,111.95 | 3,289,903.19 |
| 应付票据及应付账款 | 62,355,517,360.44 | 61,404,558,255.56 | 64,548,321,208.76 | 63,011,635,851.42 |
| 其中：应付票据 | 9,024,741,044.08 | 8,810,206,222.12 | 7,890,743,469.52 | 7,112,113,974.4 |
| 应付账款 | 53,330,776,316.36 | 52,594,352,033.44 | 56,657,577,739.24 | 55,899,521,877.02 |
| 合同负债 | 1,161,049,807.59 | 1,504,248,413.81 | 1,304,859,343.17 | 1,212,865,778.27 |
| 应付职工薪酬 | 1,472,233,748.3 | 1,922,236,416.36 | 1,834,704,586.61 | 1,564,385,094.13 |
| 应交税费 | 1,324,994,987.02 | 1,486,244,282.39 | 1,381,921,817.49 | 1,239,722,518.23 |
| 其他应付款合计 | 16,061,134,297.36 | 16,731,913,987.12 | 16,322,460,744.02 | 17,889,183,683.53 |
| 应付股利 | 544,257,913.2 | 1,074,213,335.02 | 624,228,265.18 | 1,710,839,497.1 |
| 一年内到期的非流动负债 | 2,168,532,783.96 | 2,809,599,313.1 | 3,903,432,558.78 | 3,423,071,751.58 |
| 其他流动负债 | 5,244,289,163.87 | 5,234,190,156.67 | 5,193,226,292.03 | 6,165,149,161.23 |
| 流动负债合计 | 136,508,633,684.03 | 135,198,106,270.5 | 138,990,247,902.67 | 140,131,022,109.65 |
| 非流动负债: | | | | |
| 长期借款 | 3,257,225,265.34 | 4,235,875,600.03 | 4,120,516,630.15 | 4,698,141,763.96 |
| 租赁负债 | 1,462,573,484.66 | 1,149,374,250.76 | 1,200,491,502.18 | 1,409,387,957.81 |
| 长期应付款 | 9,000,000 | 9,000,000 | - | - |
| 长期应付职工薪酬 | 45,276,033.02 | 43,678,918.22 | 61,237,650.7 | 56,795,866.12 |
| 预计负债 | 79,108,102.85 | 74,699,932.37 | 30,930,879.85 | 38,768,731.17 |
| 递延收益 | 551,504,627.18 | 573,376,479.16 | 528,973,653.19 | 603,627,624.16 |
| 递延所得税负债 | 1,827,835,209.29 | 1,945,081,137.22 | 1,916,531,484.47 | 2,023,974,550.06 |
| 其他非流动负债 | 160,809,031.42 | 132,280,455.35 | 274,691,694.9 | 247,432,904.79 |
| 非流动负债合计 | 7,393,331,753.76 | 8,163,366,773.11 | 8,133,373,495.44 | 9,078,129,398.07 |
| 负债合计 | 143,901,965,437.79 | 143,361,473,043.61 | 147,123,621,398.11 | 149,209,151,507.72 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 3,708,361,809 | 3,708,361,809 | 3,708,361,809 | 3,708,361,809 |
| 资本公积 | 29,697,956,364.44 | 29,687,120,114.88 | 29,701,717,860.25 | 29,695,514,631.31 |
| 其他综合收益 | -551,829,250.5 | -532,971,659.94 | -537,313,358.28 | -530,117,954.13 |
| 盈余公积 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 |
| 未分配利润 | 42,139,625,230.67 | 40,721,868,176.6 | 40,603,144,710.02 | 39,914,944,653.52 |
| 归属于母公司股东权益合计 | 77,301,063,537.24 | 75,891,327,824.17 | 75,782,860,404.62 | 75,095,652,523.33 |
| 少数股东权益 | 14,166,454,713.21 | 13,895,965,899.43 | 13,839,763,433.49 | 13,762,252,040.32 |
| 股东权益合计 | 91,467,518,250.45 | 89,787,293,723.6 | 89,622,623,838.11 | 88,857,904,563.65 |
| 负债和股东权益合计 | 235,369,483,688.24 | 233,148,766,767.21 | 236,746,245,236.22 | 238,067,056,071.37 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |